D J Slamon

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Advances in adjuvant therapy for breast cancer
    Dennis J Slamon
    Division of Hematology Oncology, David Geffen School of Medicine, University of California, Los Angeles, USA
    Clin Adv Hematol Oncol 4:suppl 1, 4-9; discussion suppl 10; quiz 2 p following suppl 10. 2006
  2. pmc Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells
    G E Konecny
    Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA
    Br J Cancer 98:1076-84. 2008
  3. pmc Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study
    Carolyn D Britten
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Santa Monica, CA 90404 2429, USA
    BMC Cancer 12:16. 2012
  4. pmc Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer
    Yanyuan Wu
    Divisions of Cancer Research and Training, Hematology Oncology, Department of Medicine, Charles R Drew University of Medicine and Science, 1731 East 120th Street, Los Angeles, CA 90059, USA
    Breast Cancer Res 10:R3. 2008
  5. pmc PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
    Richard S Finn
    Department of Medicine, Division of Hematology Oncology, Geffen School of Medicine at UCLA, 10833 Le Conte Ave, 11 934 Factor Bldg, Los Angeles, CA 90095, USA
    Breast Cancer Res 11:R77. 2009
  6. pmc HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells
    Cindy A Wilson
    Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Breast Cancer Res 7:R1058-79. 2005
  7. pmc Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation
    Yanyuan Wu
    Division of Cancer Research and Training, Department of Internal Medicine, Charles R, Drew University of Medicine and Science, Los Angeles, CA 90059, USA
    BMC Cancer 10:32. 2010
  8. pmc Adjuvant trastuzumab in HER2-positive breast cancer
    Dennis Slamon
    Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA 90095 1678, USA
    N Engl J Med 365:1273-83. 2011
  9. ncbi request reprint Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    D J Slamon
    Division of Hematology and Oncology, UCLA School of Medicine, Los Angeles, Calif 90095 1678, USA
    N Engl J Med 344:783-92. 2001
  10. pmc Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
    G E Konecny
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90404 2429, USA
    Br J Cancer 101:1699-708. 2009

Research Grants

  1. ACADEMIC TRAINING IN MEDICAL ONCOLOGY
    Dennis Slamon; Fiscal Year: 2005
  2. SIGNAL TRANSDUCTION IN ONCOGENESIS
    Dennis Slamon; Fiscal Year: 2006

Detail Information

Publications67

  1. ncbi request reprint Advances in adjuvant therapy for breast cancer
    Dennis J Slamon
    Division of Hematology Oncology, David Geffen School of Medicine, University of California, Los Angeles, USA
    Clin Adv Hematol Oncol 4:suppl 1, 4-9; discussion suppl 10; quiz 2 p following suppl 10. 2006
    ..Finally, new targeted agents are being investigated and ongoing research aims to identify additional potential therapeutic targets to further improve outcomes for these patients...
  2. pmc Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells
    G E Konecny
    Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA
    Br J Cancer 98:1076-84. 2008
    ..Expression of EGFR, its ligands, HER3, AR, and post-EMT markers warrant further evaluation to help define patients with HER2-nonoverexpressing endometrial cancer most likely to benefit from lapatinib...
  3. pmc Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study
    Carolyn D Britten
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Santa Monica, CA 90404 2429, USA
    BMC Cancer 12:16. 2012
    ..This pilot study examined whether intravenous (IV) bevacizumab, a monoclonal antibody against VEGF, could inhibit neovessel formation after TACE...
  4. pmc Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer
    Yanyuan Wu
    Divisions of Cancer Research and Training, Hematology Oncology, Department of Medicine, Charles R Drew University of Medicine and Science, 1731 East 120th Street, Los Angeles, CA 90059, USA
    Breast Cancer Res 10:R3. 2008
    ..Cellular and molecular studies have shown that activation of the cell signaling phosphatidylinositol-3-kinase/Akt cascade via the HER2/neu and other receptor tyrosine kinases induces cell proliferation...
  5. pmc PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
    Richard S Finn
    Department of Medicine, Division of Hematology Oncology, Geffen School of Medicine at UCLA, 10833 Le Conte Ave, 11 934 Factor Bldg, Los Angeles, CA 90095, USA
    Breast Cancer Res 11:R77. 2009
    ..To identify predictors of response, we determined the in vitro sensitivity to PD 0332991 across a panel of molecularly characterized human breast cancer cell lines...
  6. pmc HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells
    Cindy A Wilson
    Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Breast Cancer Res 7:R1058-79. 2005
    ....
  7. pmc Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation
    Yanyuan Wu
    Division of Cancer Research and Training, Department of Internal Medicine, Charles R, Drew University of Medicine and Science, Los Angeles, CA 90059, USA
    BMC Cancer 10:32. 2010
    ..Epigenetic changes associated with promoter DNA methylation results in silencing of several tumor suppressor genes that lead to increased risk for tumor formation and for progression of the cancer...
  8. pmc Adjuvant trastuzumab in HER2-positive breast cancer
    Dennis Slamon
    Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA 90095 1678, USA
    N Engl J Med 365:1273-83. 2011
    ..We wanted to evaluate the efficacy and safety of a new nonanthracycline regimen with trastuzumab...
  9. ncbi request reprint Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    D J Slamon
    Division of Hematology and Oncology, UCLA School of Medicine, Los Angeles, Calif 90095 1678, USA
    N Engl J Med 344:783-92. 2001
    ..The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30 percent of breast cancers, increasing the aggressiveness of the tumor...
  10. pmc Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
    G E Konecny
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90404 2429, USA
    Br J Cancer 101:1699-708. 2009
    ....
  11. ncbi request reprint Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer
    Gottfried E Konecny
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, and Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095 7077, USA
    J Natl Cancer Inst 96:1141-51. 2004
    ....
  12. ncbi request reprint Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib
    Neil A O'Brien
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095 7077, USA
    Mol Cancer Ther 9:1489-502. 2010
    ..In conclusion, pharmacologic targeting of the PI3K/AKT pathway may provide benefit to HER2-positive breast cancer patients who are resistant to trastuzumab therapy...
  13. ncbi request reprint A candidate tumor suppressor gene, H37, from the human lung cancer tumor suppressor locus 3p21.3
    Juliana J Oh
    Department of Medicine, University of California, Los Angeles, CA 90095, USA
    Cancer Res 62:3207-13. 2002
    ..H37 also suppressed anchorage-dependent and -independent growth of A9 mouse fibrosarcoma cells and inhibited tumor formation in nude mice. These data indicate a potential role for H37 as one of the 3p TSGs in human lung cancer...
  14. ncbi request reprint EGF activates intracellular and intercellular calcium signaling by distinct pathways in tumor cells
    Joshua A Bryant
    Department of Neurology David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California90095, USA
    Cancer Biol Ther 3:1243-9. 2004
    ..Distinct intra- and intercellular Ca2+ signaling pathways may be mechanisms by which EGF modulates the growth and migration of tumor cells...
  15. ncbi request reprint Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens
    Michael F Press
    Breast Cancer Research Program of the Lee Breast Center, Department of Pathology, University of Southern California, Los Angeles, USA
    J Clin Oncol 20:3095-105. 2002
    ..To compare and evaluate HER-2/neu clinical assay methods...
  16. ncbi request reprint HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas
    M F Press
    Norris Comprehensive Cancer Center and Department of Pathology, University of Southern California School of Medicine, Los Angeles, CA 90033, USA
    J Clin Oncol 15:2894-904. 1997
    ....
  17. ncbi request reprint Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
    M D Pegram
    Department of Medical Oncology, The University of California at Los Angeles, USA
    J Clin Oncol 16:2659-71. 1998
    ..v.) administration of recombinant, humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) plus cisplatin (CDDP) in a phase II, open-label, multicenter clinical trial for patients with HER2/neu-overexpressing metastatic breast cancer...
  18. pmc The two single nucleotide polymorphisms in the H37/RBM5 tumour suppressor gene at 3p21.3 correlated with different subtypes of non-small cell lung cancers
    Juliana J Oh
    Division of Hematology Oncology, University of California at Los Angeles School of Medicine, 11 934 Factor Building, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    Lung Cancer 58:7-14. 2007
    ..In addition, because of prevalent loss of heterozygosity (LOH) detected at 3p21.3 which precedes lung cancer initiation, these SNPs may be developed into a marker screening for the high risk individuals...
  19. ncbi request reprint Promoter methylation study of the H37/RBM5 tumor suppressor gene from the 3p21.3 human lung cancer tumor suppressor locus
    Juliana J Oh
    Division of Hematology Oncology, School of Medicine, University of California at Los Angeles, 11 934 Factor Building, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    Hum Genet 123:55-64. 2008
    ....
  20. ncbi request reprint The FUTURE of ErbB-1 and ErbB-2 pathway inhibition in breast cancer: targeting multiple receptors
    Dennis J Slamon
    Division of Hematology Oncology, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, 90095 7077, USA
    Oncologist 9:1-3. 2004
  21. ncbi request reprint 3p21.3 tumor suppressor gene H37/Luca15/RBM5 inhibits growth of human lung cancer cells through cell cycle arrest and apoptosis
    Juliana J Oh
    Division of Hematology Oncology, University of California at Los Angeles School of Medicine, 675 Charles E Young Drive South, Los Angeles, CA 90095, USA
    Cancer Res 66:3419-27. 2006
    ..Lastly, we proposed a tumor suppression model of H37 as a post-transcriptional regulator for cell cycle/apoptotic-related proteins...
  22. ncbi request reprint Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells
    Gottfried E Konecny
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, 12 145 Factor Building, 10945 Le Conte Avenue, Los Angeles, CA 90095 1678, USA
    Cancer Res 66:1630-9. 2006
    ..These observations provide a clear biological rationale to test lapatinib as a single agent or in combination with trastuzumab in HER-2-overexpressing breast cancer and in patients with clinical resistance to trastuzumab...
  23. ncbi request reprint Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro
    Richard S Finn
    Department of Medicine, Division of Hematology, Oncology Geffen School of Medicine at UCLA, 10833 Le Conte Ave, 11 934 Factor Bldg, Los Angeles, CA 90095, USA
    Breast Cancer Res Treat 105:319-26. 2007
    ..e. hormonal manipulation or trastuzumab)...
  24. doi request reprint A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach
    Carolyn D Britten
    Department of Medicine, University of California, Los Angeles, CA, USA
    Clin Breast Cancer 9:16-22. 2009
    ..This phase I/II trial was conducted to determine the toxicities, recommended dose, pharmacokinetics, and response rate of erlotinib plus trastuzumab in metastatic HER2+ breast cancer...
  25. doi request reprint Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target
    Marlena S Fejzo
    Department of Medicine, Division of Hematology Oncology, University of California, Los Angeles, Los Angeles, CA 90095, USA
    Genes Chromosomes Cancer 47:873-83. 2008
    ..Functional analysis is now warranted to determine whether ADRM1 is a target for early screening and/or therapy for ovarian cancer...
  26. doi request reprint Evaluation of well-differentiated/de-differentiated liposarcomas by high-resolution oligonucleotide array-based comparative genomic hybridization
    William D Tap
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
    Genes Chromosomes Cancer 50:95-112. 2011
    ..This detailed genetic mapping provides insight into the heterogeneity of WD and DDLS and the chromosomal and genetic abnormalities that are present in and distinguish these mesenchymal malignancies...
  27. doi request reprint A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01)
    Sara A Hurvitz
    David Geffen School of Medicine, University of California, Los Angeles, CA, USA
    Clin Breast Cancer 10:307-12. 2010
    ..To assess the activity of docetaxel plus bevacizumab, a multicenter phase II trial was conducted...
  28. doi request reprint Tissue microarrays from frozen tissues-OCT technique
    Marlena Schoenberg Fejzo
    Division of Hematology Oncology, Department of Medicine, School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA
    Methods Mol Biol 664:73-80. 2010
    ....
  29. pmc Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma
    William D Tap
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
    Neoplasia 12:637-49. 2010
    ..We sought to investigate the efficacy of PLX4032 (BRAF inhibitor) to identify patterns/predictors of response/resistance and to study the effects of BRAF in melanoma...
  30. doi request reprint Periostin promotes ovarian cancer angiogenesis and metastasis
    Min Zhu
    Division of Hematology Oncology, Department of Medicine, University of California at Los Angeles, Los Angeles, CA, USA
    Gynecol Oncol 119:337-44. 2010
    ..In the present study, we investigated PN expression status in a large cohort of ovarian tumors with the focus on biological influence of PN related on ovarian tumor angiogenesis and metastasis...
  31. pmc Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines
    Edward B Garon
    1Department of Medicine, Division of Hematology Oncology, Geffen School of Medicine at UCLA, Los Angeles, California, USA
    Mol Cancer Ther 9:1985-94. 2010
    ..In total, these results suggest that clinical trials of selumetinib in breast cancer and NSCLC might select patients whose tumors harbor raf and ras mutations, respectively...
  32. doi request reprint RBM5/H37 tumor suppressor, located at the lung cancer hot spot 3p21.3, alters expression of genes involved in metastasis
    Juliana J Oh
    Division of Hematology Oncology, University of California at Los Angeles School of Medicine, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    Lung Cancer 70:253-62. 2010
    ..Further study is warranted to evaluate the potential clinical utility of RBM5 in lung cancer diagnostics, prognostics and therapeutics...
  33. doi request reprint Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo
    Zev A Wainberg
    Department of Medicine, Division of Hematology Oncology, Geffen School of Medicine at UCLA, Los Angeles, California 90404, USA
    Clin Cancer Res 16:1509-19. 2010
    ....
  34. doi request reprint Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer
    Gottfried E Konecny
    UCLA Translational Oncology Research Lab, David Geffen School of Medicine, University of California Los Angeles, 2825 Santa Monica Blvd, Suite 200, Santa Monica, CA, 90404 2429, USA
    Breast Cancer Res Treat 120:481-9. 2010
    ..However, added benefit of IDD chemotherapy itself was not associated with HER2 or TOP2A status...
  35. ncbi request reprint Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials
    Michael F Press
    Women s Cancers Program, Department of Pathology, Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, CA 89195, USA
    Clin Cancer Res 11:6598-607. 2005
    ....
  36. ncbi request reprint Evaluation of H37, a candidate 3p21.3 tumor suppressor gene, as a therapeutic and diagnostic marker in lung cancer
    Juliana J Oh
    Division of Hematology Oncology, UCLA School of Medicine, Los Angeles, CA, USA
    Chest 125:102S-3S. 2004
  37. ncbi request reprint Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells
    M Jane Arboleda
    Department of Medicine, Division of Hematology and Oncology, University of California Los Angeles, UCLA School of Medicine, Los Angeles, California 90095, USA
    Cancer Res 63:196-206. 2003
    ..Taken together, these data indicate that AKT2 mediates PI3-K-dependent effects on adhesion, motility, invasion, and metastasis in vivo...
  38. ncbi request reprint Culture conditions affect the ability of ex vivo expanded peripheral blood progenitor cells to accelerate hematopoietic recovery
    Ronald L Paquette
    Department of Medicine, Division of Hematology Oncology, 42 121 UCLA Center for the Health Sciences, 10833 Le Conte Avenue, Los Angeles, CA 90095 1678, USA
    Exp Hematol 30:374-80. 2002
    ..The aim of this study was to evaluate the effect of various ex vivo expansion conditions on the cell products and their ability to accelerate hematopoietic recovery in patients undergoing stem cell transplantation...
  39. ncbi request reprint Monoclonal antibody therapy for breast cancer: herceptin
    Richard S Finn
    Geffen School of Medicine, UCLA, Department of Medicine, Los Angeles, CA 90095, USA
    Cancer Chemother Biol Response Modif 21:223-33. 2003
  40. ncbi request reprint Use of low-melting-point primers for bisulfite genomic sequencing: analysis of the H37 lung cancer tumor suppressor gene promoter
    Juliana J Oh
    Hematology Oncology Division, UCLA School of Medicine, Los Angeles, CA 90095, USA
    Anal Biochem 343:347-9. 2005
  41. pmc A model-based approach for assessing in vivo combination therapy interactions
    A M Lopez
    Department of Biomathematics, School of Medicine, University of California, Los Angeles, CA 90095 1766, USA
    Proc Natl Acad Sci U S A 96:13023-8. 1999
    ....
  42. ncbi request reprint Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients
    Gottfried E Konecny
    Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095 1678, USA
    Clin Cancer Res 10:1706-16. 2004
    ..compare the prognostic significance of VEGF isoforms; and (c). analyze the combined effects of HER-2/neu and VEGF on clinical outcome...
  43. ncbi request reprint Expression of c-Fes protein isoforms correlates with differentiation in myeloid leukemias
    Anne Carlson
    Division of Hematology Oncology, Department of Medicine and Jonsson Comprehensive Cancer Center, UCLA School of Medicine, Los Angeles, California, USA
    DNA Cell Biol 24:311-6. 2005
    ..We infer that alternative splicing generates a family of c-Fes proteins. This may be a mechanism to direct the c-Fes kinase domain to different subcellular locations and/or substrates at specific stages of myeloid cell differentiation...
  44. ncbi request reprint Ex vivo expanded unselected peripheral blood: progenitor cells reduce posttransplantation neutropenia, thrombocytopenia, and anemia in patients with breast cancer
    R L Paquette
    Departments of Medicine and Biostatistics, University of California at Los Angeles, Los Angeles, CA, USA
    Blood 96:2385-90. 2000
    ..Therefore, ex vivo expanded PBPC are capable of ameliorating posttransplantation neutropenia, thrombocytopenia, and anemia in patients receiving high-dose chemotherapy...
  45. pmc Frozen tumor tissue microarray technology for analysis of tumor RNA, DNA, and proteins
    M Schoenberg Fejzo
    Division of Hematology Oncology, Department of Medicine, University of California, Los Angeles, School of Medicine, Los Angeles, California, USA
    Am J Pathol 159:1645-50. 2001
    ..We show OCT arrays work well for DNA, RNA, and protein analyses, and may have significant advantages over the original technology for the assessment of some genes and proteins by improving both qualitative and quantitative results...
  46. ncbi request reprint The transmembrane heregulin precursor is functionally active
    Z Aguilar
    Department of Medicine, Division of Hematology/Oncology, UCLA School of Medicine, Los Angeles, California 90024, USA
    J Biol Chem 276:44099-107. 2001
    ..This study demonstrates that transmembrane heregulin is functionally active and suggest it is capable of playing a role in cell-cell communication and subsequent signal transduction in vivo...
  47. ncbi request reprint Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide
    C P Reynolds
    Division of Hematology Oncology, Childrens Hospital Los Angeles, Los Angeles, California 90027, USA
    Med Pediatr Oncol 35:597-602. 2000
    ..High-dose, pulse-13-cis-retinoic acid (13-cis-RA) given after intensive cytotoxic therapy improves event-free survival for high-risk neuroblastoma (NB), but more than 50% of patients have tumor recurrence...
  48. ncbi request reprint Spatial and temporal changes in the subcellular localization of the nuclear protein-tyrosine kinase, c-Fes
    Anne Carlson
    Division of Hematology Oncology, Department of Medicine, UCLA School of Medicine and Jonsson Comprehensive Cancer Center, Los Angeles, California, USA
    DNA Cell Biol 24:225-34. 2005
    ..The timing of c-Fes' appearance at the centromere coincides with the period of kinetochore assembly. These data suggest that c-Fes is recruited to the kinetochore during mitosis...
  49. ncbi request reprint Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas
    C A Wilson
    Department of Medicine, UCLA School of Medicine, Los Angeles, California 90095, USA
    Nat Genet 21:236-40. 1999
    ..Conversely, BRCA1 expression was reduced or undetectable in the majority of high-grade, ductal carcinomas, suggesting that absence of BRCA1 may contribute to the pathogenesis of a significant percentage of sporadic breast cancers...
  50. pmc Identification of differentially expressed genes associated with HER-2/neu overexpression in human breast cancer cells
    J J Oh
    Department of Medicine, Division of Hematology and Oncology, UCLA School of Medicine, Los Angeles, CA 90095 1678, USA
    Nucleic Acids Res 27:4008-17. 1999
    ..Further characterization of these genes may yield insight into the fundamental biology and pathogenetic effects of HER-2/ neu overexpression in human breast and ovarian cancer cells...
  51. ncbi request reprint ERCC5 is a novel biomarker of ovarian cancer prognosis
    Christine S Walsh
    Department of Obstetrics and Gynecology, Cedars Sinai Women s Cancer Research Institute, Samuel Oschin Comprehensive Cancer Institute, David Geffen School of Medicine, University of California at Los Angeles, CA 90048, USA
    J Clin Oncol 26:2952-8. 2008
    ..Gene expression analyses were performed through microarray experiments. Candidate genes were tested for independent effects on survival using Cox proportional hazards models, Kaplan-Meier survival curves, and the log-rank test...
  52. ncbi request reprint Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab
    Robert D Mass
    Genentech, Inc, South San Francisco, CA 94080, USA
    Clin Breast Cancer 6:240-6. 2005
    ..Breast cancer tissue specimens were evaluated using a direct labeled, dual-probe FISH assay...
  53. ncbi request reprint Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer
    Jennifer A Byrne
    Molecular Oncology Laboratory, Oncology Research Unit, The University of Sydney Discipline of Paediatrics and Child Health, The Children s Hospital at Westmead, New South Wales, Australia
    Int J Cancer 117:1049-54. 2005
    ..TPD52 therefore represents a novel molecular marker in ovarian cancer, which is broadly expressed across the different histologic subtypes and whose upregulation frequently reflects increased TPD52 copy number...
  54. ncbi request reprint Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer
    Judith Hurley
    Sylvester Cancer Center, Miller School of Medicine, University of Miami, Miami, FL 33136, USA
    J Clin Oncol 24:1831-8. 2006
    ..To evaluate the efficacy and safety of docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2 (HER2) -positive, locally advanced breast cancer (LABC)...
  55. ncbi request reprint First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors
    Pamela N Munster
    Department of Interdisciplinary Oncology, Experimental Therapeutics Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Clin Cancer Res 13:1238-45. 2007
    ..To test the tolerability, safety, and recommended phase II dose of CP-724,714, a reversible, highly selective, oral HER2 tyrosine kinase inhibitor in patients with advanced solid tumor malignancies that express HER2...
  56. ncbi request reprint Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
    Charles L Vogel
    University of Miami School of Medicine, Comprehensive Cancer Research Group Inc, and Columbia Cancer Research Network of Florida, Miami, FL, USA
    J Clin Oncol 20:719-26. 2002
    ..To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic breast cancer...
  57. ncbi request reprint Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab
    Lee W Jones
    Department of Surgery, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    Cancer Epidemiol Biomarkers Prev 16:1026-31. 2007
    ..We measured 14 metabolic and vascular established cardiovascular disease (CVD) risk factors, body mass index, cardiorespiratory fitness, and left ventricular systolic function. All assessments were done within a 14-day period...
  58. ncbi request reprint Evolving understanding of growth regulation in human breast cancer: interactions of the steroid and peptide growth regulatory pathways
    Cindy A Wilson
    J Natl Cancer Inst 97:1238-9. 2005
  59. ncbi request reprint Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer
    David Osoba
    Quality of Life Consulting, West Vancouver, British Columbia, Canada
    J Clin Oncol 20:3106-13. 2002
    ....
  60. ncbi request reprint Cyclin D1 amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumors
    Ali Namazie
    Division of Head and Neck Surgery, University of California Los Angeles School of Medicine, USA
    Laryngoscope 112:472-81. 2002
    ..Detection of cyclin D1 amplification and p16 deletion using a simple and sensitive method will be valuable for the development of effective treatment modalities for head and neck cancer...
  61. ncbi request reprint HER2 testing and correlation with efficacy of trastuzumab therapy
    Gottfried Konecny
    Oncology (Williston Park) 16:1576, 1578. 2002
  62. ncbi request reprint Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer
    Mark D Pegram
    Oncology Research Network, David Geffen School of Medicine, and Division of Hematology Oncology, University of California, Los Angeles 90095 7077, USA
    J Natl Cancer Inst 96:759-69. 2004
    ....
  63. ncbi request reprint Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer
    Gottfried Konecny
    Division of Hematology Oncology, Department of Medicine, and Jonsson Comprehensive Cancer Center, University of California at Los Angeles School of Medicine, Los Angeles 90095 1678, USA
    J Natl Cancer Inst 95:142-53. 2003
    ..To better understand the relationship between HER-2/neu positivity and HR expression, we analyzed HER-2/neu, ER, and PR as continuous variables in breast cancer cell lines and two cohorts of primary breast cancer patients...
  64. ncbi request reprint Is there a role for epidermal growth factor receptor inhibitors in breast cancer prevention?
    Gottfried E Konecny
    J Natl Cancer Inst 95:1813-5. 2003
  65. ncbi request reprint Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer
    Mark D Pegram
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles 90095 7077, USA
    J Natl Cancer Inst 96:739-49. 2004
    ..We characterized interactions between trastuzumab and chemotherapeutic agents commonly used in the treatment of breast cancer...
  66. ncbi request reprint Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression
    Debu Tripathy
    University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390 8852, USA
    J Clin Oncol 22:1063-70. 2004
    ..We conducted an extension study to this trial to obtain additional safety information and to provide trastuzumab following disease progression...
  67. ncbi request reprint Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development
    John W Park
    University of California, San Francisco Cancer Center, San Francisco, California 94115 1710, USA
    Clin Cancer Res 10:3885-96. 2004

Research Grants2

  1. ACADEMIC TRAINING IN MEDICAL ONCOLOGY
    Dennis Slamon; Fiscal Year: 2005
    ..This application seeks support for the critical and pivotal 2-year period which transitions the trainee from his/her initial clinical oncology experience to a career in academic medical oncology. ..
  2. SIGNAL TRANSDUCTION IN ONCOGENESIS
    Dennis Slamon; Fiscal Year: 2006
    ..We feel the likelihood of important findings in both basic and translational research results from these efforts is high. ..